Investigational New Drugs

, Volume 37, Issue 5, pp 1036–1043 | Cite as

Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo

  • Juan MaEmail author
  • Tengfei Shang
  • Pan Ma
  • Xin Sun
  • Jin Zhao
  • Ximing Sun
  • Man ZhangEmail author


Inhibition of the B7-H3 immune checkpoint is reported to limit the tumor growth of B7-H3+ tumors. In this study, we demonstrated B7-H3 expression in human melanoma cells, including a primary culture and several cell lines. Furthermore, we investigated whether B7-H3 could serve as a target for T cell-mediated immunotherapy against melanoma. The cytotoxic capacity of activated T cells (ATCs) armed with an anti-CD3 x anti-B7-H3 bispecific antibody (B7-H3Bi-Ab) to melanoma cells was measured using a bioluminescent signal through a luciferase reporter on tumor cells. In contrast to unarmed ATCs, B7-H3Bi-Ab-armed ATCs exhibited increased cytotoxicity against melanoma cells at effector/target ratios from 1:1 to 20:1. Moreover, B7-H3Bi-Ab-armed ATCs secreted more interferin-gamma (IFN-γ), accompanied by higher levels of activating marker CD69 and CD25 expression. Infusion of B7-H3Bi-Ab-armed ATCs suppressed melanoma growth in a xenograft mouse model. Taken together, our results indicate that B7-H3Bi-Ab-armed ATCs may be a promising approach to immunotherapy for melanoma patients.


Melanoma B7-H3 Bispecific antibody Immunotherapy 



This work is funded by grants from the National Nature Science Foundation of China (No.31400754) and Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20150701).

Compliance with ethical standards

Conflicts of interest

Juan Ma, Tengfei Shang, Pan Ma, Xin Sun, Jin Zhao, Ximing Sun, and Man Zhang declare that they have no conflicts of interest.

Ethical approval

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee. The animal study complied with the Guide for the Care and Use of Laboratory Animals of the Ministry of Health, and the protocol was approved by the Ethics Committee of Beijing Shijitan Hospital of Capital Medical University.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRefGoogle Scholar
  2. 2.
    Dillman RO, CornforthAN DC, McClay EF, Amatruda TT, de Leon C, Ellis RE, Mayorga C, Carbonell D, Cubellis JM (2012) Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother 35(8):641–649CrossRefGoogle Scholar
  3. 3.
    Ullenhag GJ, Sadeghi AM, Carlsson B, Ahlström H, Mosavi F, Wagenius G, Tötterman TH (2012) Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. Cancer Immunol Immunother 61 (5):725–732CrossRefGoogle Scholar
  4. 4.
    Larkin J, Chiarion-Sileni V, Gonzaler R, Grob JJ, Cowey CL, Lao CD, Schadedof D, Dummer R, Smylie M, Rutkowki P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horek C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34CrossRefGoogle Scholar
  5. 5.
    Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, Zlabinger G, Pickl WF, Stöckl J, Knapp W (2004) Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172(4):2352–2359CrossRefGoogle Scholar
  6. 6.
    Leitner J, Klauser C, Pickl WF, Stöckl J, Majdic O, Bardet AF, Kreil DP, Dong C, Yamazaki T, Zlabinger G, Pfistershammer K, Steinberger P (2009) B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction. Eur J Immunol 39(7):1754–1764CrossRefGoogle Scholar
  7. 7.
    Wang L, Kang FB, Shan BE (2014) B7-H3-mediated tumor immunology: Friend or foe? Int J Cancer 134(12):2764–2771CrossRefGoogle Scholar
  8. 8.
    Picarda E, Ohaegbulam KC, Zan g X (2016) Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res 22(14):3425–3431CrossRefGoogle Scholar
  9. 9.
    Castellanos JR, Purvis IJ, Labak CM, Guda MR, Tsung AJ, Velpula KK, Asuthkar S (2017) B7-H3 role in the immune landscape of cancer. Am J Clin Exp Immunol 6(4):66–75Google Scholar
  10. 10.
    Wang J, Chong KK, Nakamura Y, Nguyen L, Huang SK, Kuo C, Zhang W, Yu H, Morton DL, Hoon DS (2013) B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol 133(8):2050–2058CrossRefGoogle Scholar
  11. 11.
    Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, Fodstad O (2012) B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer 130(10):2282–2290CrossRefGoogle Scholar
  12. 12.
    Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE (2017) Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells. Pigment Cell Melanoma Res 30(5):467–476CrossRefGoogle Scholar
  13. 13.
    Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, Xiong W, Zang W, Guo L, Liu Y, Dong ZJ, Overwijk WW, Hwu P, Yi Q, Kwak L, Yang Z, Mak TW, Li W, Radvanyi LG, Ni L, Liu D, Dong C (2017) Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res 27(8):1034–1045CrossRefGoogle Scholar
  14. 14.
    Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton AN, Li JC, Rillema JR, Licea M, Fieger C, Liang TW, Mather JP, Koenig S, Stewart SJ, Johnson S, Bonvini E, Moore PA (2012) Development of an Fc-enhanced anti–B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res 18(14):3834–3845CrossRefGoogle Scholar
  15. 15.
    Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, Humm JL, Xu H, Wolden SL, Souweidane MM, Larson SM, Cheung NK (2010) Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neuro-Oncol 97(3):409–418CrossRefGoogle Scholar
  16. 16.
    Lum LG, Thakur A (2011) Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs 25(6):365–379CrossRefGoogle Scholar
  17. 17.
    Bhutani D, Lum LG (2015) Activated T cells armed with bispecific antibodies kill tumor targets. Curr Opin Hematol 22(6):476–483CrossRefGoogle Scholar
  18. 18.
    Ma J, Ma P, Zhao C, Xue X, Han H, Liu C, Tao H, Xiu W, Cai J, Zhang M (2016) B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. Oncotarget 7(20):29480–29491Google Scholar
  19. 19.
    Ma J, Han H, Liu D, Li W, Feng H, Xue X, Wu X, Niu G, Zhang G, Zhao Y, Liu C, Tao H, Gao B (2013) HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. PLoS One 8(8):e73261CrossRefGoogle Scholar
  20. 20.
    Fousek K, Ahmed N (2015) The evolution of T-cell therapies for solid malignancies. Clin Cancer Res 21(15):3384–3392CrossRefGoogle Scholar
  21. 21.
    Yu S, Li A, Liu Q, Yuan X, Xu H, Jiao D, Pestell RG, Han X, Wu K (2017) Recent advances of bispeicific antibodies in solid tumors. J Hematol Oncol 10(1):15CrossRefGoogle Scholar
  22. 22.
    Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R (2015) Targeted T-cell therapy in stage IV breast cancer: a phase I clinical trial. Clin Cancer Res 21(10):2305–2314CrossRefGoogle Scholar
  23. 23.
    Vaishampayan U, Thakur A, Rathore R, Kouttab N, Lum LG (2015) Phase I Study of Anti-CD3 x anti-Her2 bispecific antibody in metastatic castrate resistant prostate cancer patients. Prostate Cancer 2015:285193CrossRefGoogle Scholar
  24. 24.
    Tiffen JC, Bailey CG, Ng C, Rasko JE, Holst J (2010) Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. MolCancer 9:299Google Scholar
  25. 25.
    Sathaliyawala T, Kubota M, Yudanin N, Turner D, Camp P, Thome JJ, Bickham KL, Lerner H, Goldstein M, Sykes M, Kato T, Farber DL (2013) Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 38(1):187–197CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Clinical Laboratory Medicine, Beijing Shijitan HospitalCapital Medical UniversityBeijingChina
  2. 2.Clinical Laboratory MedicinePeking University Ninth School of Clinical MedicineBeijingChina
  3. 3.Beijing Key Laboratory of Urinary Cellular Molecular DiagnosticsBeijingChina
  4. 4.Medical Experimental CentreChina Academy of Chinese Medical SciencesBeijingChina
  5. 5.Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of BiophysicsChinese Academy of SciencesBeijingChina

Personalised recommendations